Therapeutic thrombolysis for acute ischaemic stroke

British Medical Journal

Volumn 326, Issue 7383, 2003, Pages 233-234

  Warlow, Charles ^a   Wardlaw, Jonna ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT;

ACUTE HEART INFARCTION; ATHEROMA; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; EDITORIAL; HUMAN; LONG TERM CARE; NEUROPROTECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT PLANNING;

EID: 0037309948     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.326.7383.233     Document Type: Editorial

References (5)

1. Rothwell PM. The high cost of not funding stroke research: a comparison with heart disease and cancer. Lancet 2001;357:1612-6.
2. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
3. Wardlaw JM, del Zoppo GJ, Yamaguchi T, Berge E. Thrombolysis in acute ischaemic stroke. Cochrane Database Syst Rev 2000;(2):CD000213.
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
5. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JJ, Wang DZ. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischaemic stroke treated in community hospitals. Stroke 2001;32:1832-40.